HeartWare Touts Early Success In U.S. Launch Of HVAD
This article was originally published in The Gray Sheet
HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.
You may also be interested in...
Results of the 446-patient trial presented at the International Society for Heart and Lung Transplantation Annual Meeting show non-inferiority of the HVAD to FDA-approved ventricular assist devices in destination therapy patients.
The acquisition could significantly expand the targeted market base for HeartWare, but first the company will need to re-launch CircuLite’s Synergy in Europe, which experiences a design problem the first time around.